Rituximab in Subepidermal Blistering Diseases

Area of Science:

• Immunodermatology
• Autoimmune Blistering Diseases
• Pharmacological Therapies

Background:

• The efficacy of rituximab in pemphigus is established, but its use in subepidermal autoimmune blistering diseases (SABDs) is off-label and poorly understood.
• Subepidermal autoimmune blistering diseases encompass conditions like bullous pemphigoid, mucous membrane pemphigoid, ocular pemphigoid, and epidermolysis bullosa acquisita.

Approach:

• A meta-analysis was conducted on case reports, case series, and retrospective studies.
• Effectiveness and safety of rituximab in SABDs were evaluated by comparing remission and relapse rates against conventional therapy.
• Subgroup analyses were performed across different SABD classifications.

Key Points:

• Patients with SABDs treated with rituximab demonstrated a higher rate of complete remission.
• The interval to the first relapse was significantly longer in patients receiving rituximab.
• No increase in adverse events or mortality was observed in the rituximab group compared to controls.

Conclusions:

• Rituximab shows potential as an effective treatment for subepidermal autoimmune blistering diseases, improving remission rates and delaying relapse.
• Current evidence is limited by the retrospective nature of studies and the frequent use of rituximab as a rescue therapy.
• Randomized controlled trials are essential to validate these findings and establish rituximab's role in SABD management.